160 related articles for article (PubMed ID: 36846137)
1. Research progress on the protective mechanism of a novel soluble epoxide hydrolase inhibitor TPPU on ischemic stroke.
Huang P
Front Neurol; 2023; 14():1083972. PubMed ID: 36846137
[TBL] [Abstract][Full Text] [Related]
2. Protective Effects of the Soluble Epoxide Hydrolase Inhibitor 1-Trifluoromethoxyphenyl-3-(1-Propionylpiperidin-4-yl) Urea in a Rat Model of Permanent Middle Cerebral Artery Occlusion.
Zhang L; Xu S; Wu X; Muse FM; Chen J; Cao Y; Yan J; Cheng Z; Yi X; Han Z
Front Pharmacol; 2020; 11():182. PubMed ID: 32184732
[TBL] [Abstract][Full Text] [Related]
3. 1-Trifluoromethoxyphenyl-3-(1-Propionylpiperidin-4-yl) Urea Protects the Blood-Brain Barrier Against Ischemic Injury by Upregulating Tight Junction Protein Expression, Mitigating Apoptosis and Inflammation
Yi X; Xu C; Huang P; Zhang L; Qing T; Li J; Wang C; Zeng T; Lu J; Han Z
Front Pharmacol; 2020; 11():1197. PubMed ID: 32848796
[TBL] [Abstract][Full Text] [Related]
4. Soluble epoxide hydrolase inhibition decreases reperfusion injury after focal cerebral ischemia.
Tu R; Armstrong J; Lee KSS; Hammock BD; Sapirstein A; Koehler RC
Sci Rep; 2018 Mar; 8(1):5279. PubMed ID: 29588470
[TBL] [Abstract][Full Text] [Related]
5. A Soluble Epoxide Hydrolase Inhibitor, 1-TrifluoromethoxyPhenyl-3-(1-Propionylpiperidin-4-yl) Urea, Ameliorates Experimental Autoimmune Encephalomyelitis.
Jonnalagadda D; Wan D; Chun J; Hammock BD; Kihara Y
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33925035
[TBL] [Abstract][Full Text] [Related]
6.
Wan D; Yang J; McReynolds CB; Barnych B; Wagner KM; Morisseau C; Hwang SH; Sun J; Blöcher R; Hammock BD
Front Pharmacol; 2019; 10():464. PubMed ID: 31143115
[TBL] [Abstract][Full Text] [Related]
7. 1-trifluoromethoxyphenyl-3-(1-propionylpiperidin-4-yl) Urea Exerts Neuro-Protective Effects Against Ischemic Injury via Suppressing JNK/p38 MAPK-Mediated Mitochondrial Apoptosis Pathway.
Yi X; Fan D; Yi T; Chen H; Qing T; Han Z; Bao S
J Stroke Cerebrovasc Dis; 2021 Sep; 30(9):105957. PubMed ID: 34217066
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of soluble epoxide hydrolase alleviates insulin resistance and hypertension via downregulation of SGLT2 in the mouse kidney.
Luo J; Hu S; Fu M; Luo L; Li Y; Li W; Cai Y; Dong R; Yang Y; Tu L; Xu X
J Biol Chem; 2021; 296():100667. PubMed ID: 33864813
[TBL] [Abstract][Full Text] [Related]
9. Soluble epoxide hydrolase inhibitor promotes immunomodulation to inhibit bone resorption.
Napimoga MH; Rocha EP; Trindade-da-Silva CA; Demasi APD; Martinez EF; Macedo CG; Abdalla HB; Bettaieb A; Haj FG; Clemente-Napimoga JT; Inceoglu B; Hammock BD
J Periodontal Res; 2018 Oct; 53(5):743-749. PubMed ID: 29851077
[TBL] [Abstract][Full Text] [Related]
10. Soluble epoxide hydrolase inhibitor (TPPU) alleviates ferroptosis by regulating CCL5 after intracerebral hemorrhage in mice.
Wu Q; Jiang N; Wang Y; Song G; Li P; Fang Y; Xu L; Wang W; Xie M
Biomed Pharmacother; 2024 Mar; 172():116301. PubMed ID: 38377737
[TBL] [Abstract][Full Text] [Related]
11. Soluble Epoxide Hydrolase Inhibitor Suppresses the Expression of Triggering Receptor Expressed on Myeloid Cells-1 by Inhibiting NF-kB Activation in Murine Macrophage.
Dong L; Zhou Y; Zhu ZQ; Liu T; Duan JX; Zhang J; Li P; Hammcok BD; Guan CX
Inflammation; 2017 Feb; 40(1):13-20. PubMed ID: 27696333
[TBL] [Abstract][Full Text] [Related]
12. Oral treatment of rodents with soluble epoxide hydrolase inhibitor 1-(1-propanoylpiperidin-4-yl)-3-[4-(trifluoromethoxy)phenyl]urea (TPPU): Resulting drug levels and modulation of oxylipin pattern.
Ostermann AI; Herbers J; Willenberg I; Chen R; Hwang SH; Greite R; Morisseau C; Gueler F; Hammock BD; Schebb NH
Prostaglandins Other Lipid Mediat; 2015 Sep; 121(Pt A):131-7. PubMed ID: 26117215
[TBL] [Abstract][Full Text] [Related]
13. Soluble Epoxide Hydrolase Pharmacological Inhibition Decreases Alveolar Bone Loss by Modulating Host Inflammatory Response, RANK-Related Signaling, Endoplasmic Reticulum Stress, and Apoptosis.
Trindade-da-Silva CA; Bettaieb A; Napimoga MH; Lee KSS; Inceoglu B; Ueira-Vieira C; Bruun D; Goswami SK; Haj FG; Hammock BD
J Pharmacol Exp Ther; 2017 Jun; 361(3):408-416. PubMed ID: 28356494
[TBL] [Abstract][Full Text] [Related]
14. Soluble epoxide hydrolase inhibitor trifluoromethoxyphenyl-3-(1-propionylpiperidin-4-yl)urea prevents hyperalgesia through regulating NLRC4 inflammasome-related pro-inflammatory and anti-inflammatory signaling pathways in the lipopolysaccharide-induced pain mouse model.
Cagli A; Senol SP; Temiz-Resitoglu M; Guden DS; Sari AN; Sahan-Firat S; Tunctan B
Drug Dev Res; 2021 Sep; 82(6):815-825. PubMed ID: 33559150
[TBL] [Abstract][Full Text] [Related]
15. 1-trifluoromethoxyphenyl-3(1-propionylpiperidin-4-yl) urea (TPPU), a soluble epoxide hydrolase inhibitor attenuates high fat diet-induced cardiovascular and metabolic disorders in rats.
Bukhari IA; Mohamed OY; Mahmood A; Alfadda AA; Almotrefi AA
Eur Rev Med Pharmacol Sci; 2021 Jan; 25(10):3835-3847. PubMed ID: 34109592
[TBL] [Abstract][Full Text] [Related]
16. Soluble epoxide hydrolase inhibition improves cognitive function and parenchymal artery dilation in a hypertensive model of chronic cerebral hypoperfusion.
Matin N; Fisher C; Lansdell TA; Hammock BD; Yang J; Jackson WF; Dorrance AM
Microcirculation; 2021 Jan; 28(1):e12653. PubMed ID: 32767848
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of soluble epoxide hydrolase attenuates hepatic fibrosis and endoplasmic reticulum stress induced by carbon tetrachloride in mice.
Harris TR; Bettaieb A; Kodani S; Dong H; Myers R; Chiamvimonvat N; Haj FG; Hammock BD
Toxicol Appl Pharmacol; 2015 Jul; 286(2):102-11. PubMed ID: 25827057
[TBL] [Abstract][Full Text] [Related]
18. An epoxide hydrolase inhibitor reduces neuroinflammation in a mouse model of Alzheimer's disease.
Ghosh A; Comerota MM; Wan D; Chen F; Propson NE; Hwang SH; Hammock BD; Zheng H
Sci Transl Med; 2020 Dec; 12(573):. PubMed ID: 33298560
[TBL] [Abstract][Full Text] [Related]
19. The contribution of chymase-dependent formation of ANG II to cardiac dysfunction in metabolic syndrome of young rats: roles of fructose and EETs.
Froogh G; Kandhi S; Duvvi R; Le Y; Weng Z; Alruwaili N; Ashe JO; Sun D; Huang A
Am J Physiol Heart Circ Physiol; 2020 Apr; 318(4):H985-H993. PubMed ID: 32167781
[TBL] [Abstract][Full Text] [Related]
20. Soluble epoxide hydrolase inhibitor, TPPU, increases regulatory T cells pathway in an arthritis model.
Trindade-da-Silva CA; Clemente-Napimoga JT; Abdalla HB; Rosa SM; Ueira-Vieira C; Morisseau C; Verri WA; Montalli VAM; Hammock BD; Napimoga MH
FASEB J; 2020 Jul; 34(7):9074-9086. PubMed ID: 32400048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
